Use: Labeled indications
- INDICATIONS AND USAGE Cefadroxil is indicated for the treatment of patients with infection caused by susceptible strains of the designated organisms in the following diseases: Urinary tract infections caused by E. coli…
Full indications and usage US FDA label
INDICATIONS AND USAGE Cefadroxil is indicated for the treatment of patients with infection caused by susceptible strains of the designated organisms in the following diseases: Urinary tract infections caused by E. coli, P. mirabilis, and Klebsiella species. Skin and skin structure infections caused by staphylococci and/or streptococci.
Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes (Group A beta-hemolytic streptococci). Note: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefadroxil is generally effective in the eradication of streptococci from the oropharynx.
However, data establishing the efficacy of cefadroxil for the prophylaxis of subsequent rheumatic fever are not available. Note: Culture and susceptibility tests should be initiated prior to and during therapy. Renal function studies should be performed when indicated. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefadroxil and other antibacterial drugs, cefadroxil should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.
When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemology and susceptibility patterns may contribute to the empiric selection of therapy.
Contraindications
- Known allergy to cephalosporins
Contraindications (US label) US FDA label
CONTRAINDICATIONS Cefadroxil is contraindicated in patients with known allergy to the cephalosporin group of antibiotics.
Dosing: Adult
- Uncomplicated lower urinary tract infection: 1 or 2 g/day once daily or divided twice daily
- Other urinary tract infections: 2 g/day divided twice daily
- Skin and skin structure infections: 1 g/day once or divided twice daily
- Group A streptococcal pharyngitis or tonsillitis: 1 g/day once or divided twice daily for 10 days
- CrCl 50 mL/min/1.73 m2 or less: 1 g first, then 500 mg every 12 (25–50), 24 (10–25) or 36 hours (0–10)
Dosage and administration (US label) US FDA label
DOSAGE AND ADMINISTRATION Cefadroxil is acid-stable and may be administered orally without regard to meals. Administration with food may be helpful in diminishing potential gastrointestinal complaints occasionally associated with oral cephalosporin therapy. Adults Urinary Tract Infections: For uncomplicated lower urinary tract infections (i.e., cystitis) the usual dosage is 1 or 2 g per day in a single (q.d.) or divided doses (b.i.d.).
For all other urinary tract infections the usual dosage is 2 g per day in divided doses (b.i.d.). Skin and Skin Structure Infections: For skin and skin structure infections the usual dosage is 1 g per day in single (q.d.) or divided doses (b.i.d.). Pharyngitis and Tonsillitis: Treatment of group A beta-hemolytic streptococcal pharyngitis and tonsillitis—1 g per day in single (q.d.) or divided doses (b.i.d.) for 10 days.
Children For urinary tract infections, the recommended daily dosage for children is 30 mg/kg/day in divided doses every 12 hours. For pharyngitis, tonsillitis, and impetigo, the recommended daily dosage for children is 30 mg/kg/day in a single dose or in equally divided doses every 12 hours. For other skin and skin structure infections, the recommended daily dosage is 30 mg/kg/day in equally divided doses every 12 hours.
In the treatment of beta-hemolytic streptococcal infections, a therapeutic dosage of cefadroxil should be administered for at least 10 days. Renal Impairment In patients with renal impairment, the dosage of cefadroxil should be adjusted according to creatinine clearance rates to prevent drug accumulation. The following schedule is suggested.
In adults, the initial dose is 1000 mg of cefadroxil and the maintenance dose (based on the creatinine clearance rate [mL/min/1.73 m²]) is 500 mg at the time intervals listed below. Creatinine Clearances Dosage Interval 0 to 10 mL/min 36 hours 10 to 25 mL/min 24 hours 25 to 50 mL/min 12 hours Patients with creatinine clearance rates over 50 mL/min may be treated as if they were patients having normal renal function.
Dosing: Altered kidney function
Over 90% of cefadroxil is excreted unchanged in urine within 24 hours. The US label treats creatinine clearance (CrCl) above 50 mL/min/1.73 m2 as normal; below that it gives a 1 g first dose and then 500 mg every 12, 24 or 36 hours as kidney function falls. About 63% of a dose was removed in a 6- to 8-hour hemodialysis.
Kidney function measure: Label uses CrCl in mL/min/1.73 m2; bands at 50, 25 and 10. The mL/min/1.73 m2 unit is the label's own convention and is kept verbatim.
Show full dosing details
- CrCl ≥60 mL/min/1.73 m2
- CrCl above 50: usual dose (label).
- CrCl 30–59 mL/min/1.73 m2
- CrCl 51–59: usual dose. CrCl 30–50 (label row 25–50): Initial dose 1,000 mg, then 500 mg every 12 hours (label).
- CrCl 15–29 mL/min/1.73 m2
- CrCl 25–29: Initial dose 1,000 mg, then 500 mg every 12 hours. CrCl 15–24 (label row 10–25): Initial dose 1,000 mg, then 500 mg every 24 hours (label).
- CrCl <15 mL/min/1.73 m2 (not on dialysis)
- CrCl 10–14: Initial dose 1,000 mg, then 500 mg every 24 hours. CrCl 0–10: Initial dose 1,000 mg, then 500 mg every 36 hours (label).
- Hemodialysis (intermittent)
- No hemodialysis dosing in label. A 6- to 8-hour session removed about 63% of a 1 g dose in anuric patients (label). Specialist input.
- Peritoneal dialysis
- No peritoneal dialysis dosing in label. Specialist input.
- CRRT
- Not in label; the cited CRRT review (Li 2020) gives no regimen for this drug. Specialist input.
- Dialyzable? Yes: about 63% of a 1 g dose removed during a 6- to 8-hour hemodialysis (label).
- Monitoring CrCl for dose; kidney function tests when indicated (label); diarrhea (CDAD).
Children (kidney dosing)
Show full dosing details
- eGFR ≥60
- Usual pediatric dose (label).
- eGFR 30–59
- No pediatric kidney dosing in label (the CrCl table is for adults). Specialist input.
- eGFR 15–29
- No pediatric kidney dosing in label (the CrCl table is for adults). Specialist input.
- eGFR <15 (not on dialysis)
- No pediatric kidney dosing in label (the CrCl table is for adults). Specialist input.
- Hemodialysis (intermittent)
- No pediatric kidney dosing in label. Specialist input.
- Peritoneal dialysis
- No pediatric kidney dosing in label. Specialist input.
- CRRT
- No pediatric kidney dosing in label. Specialist input.
Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.
renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.
US label text: Renal impairment US FDA label
Renal Impairment In patients with renal impairment, the dosage of cefadroxil should be adjusted according to creatinine clearance rates to prevent drug accumulation. The following schedule is suggested. In adults, the initial dose is 1000 mg of cefadroxil and the maintenance dose (based on the creatinine clearance rate [mL/min/1.73 m²]) is 500 mg at the time intervals listed below.
Creatinine Clearances Dosage Interval 0 to 10 mL/min 36 hours 10 to 25 mL/min 24 hours 25 to 50 mL/min 12 hours Patients with creatinine clearance rates over 50 mL/min may be treated as if they were patients having normal renal function.
Dosing: Pediatric
- Approved ages
- Children (label dosing by weight).
- Usual dose
- Urinary tract infections: 30 mg/kg/day divided every 12 hours; pharyngitis, tonsillitis, impetigo: 30 mg/kg/day as one or two doses (label).
- Maximum dose
- Adult dose (label).
Kidney dosing in children: see Dosing: Altered kidney function.
renalcarematters.com, reviewedPediatric use (US label) US FDA label
Pediatric Use (See DOSAGE AND ADMINISTRATION.)
Dosing: Older adult
Geriatric use (US label) US FDA label
Geriatric Use Of approximately 650 patients who received cefadroxil for the treatment of urinary tract infections in three clinical trials, 28% were 60 years and older, while 16% were 70 years and older. Of approximately 1000 patients who received cefadroxil for the treatment of skin and skin structure infection in 14 clinical trials, 12% were 60 years and older while 4% were 70 years and over.
No overall differences in safety were observed between the elderly patients in these studies and younger patients. Clinical studies of cefadroxil for the treatment of pharyngitis or tonsillitis did not include sufficient numbers of patients 65 years and older to determine whether they respond differently from younger patients.
Other reported clinical experience with cefadroxil has not identified differences in responses between elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. Cefadroxil is substantially excreted by the kidney, and dosage adjustment is indicated for patients with renal impairment (see DOSAGE AND ADMINISTRATION: Renal Impairment).
Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.
Dosage forms
Philippines
- Capsule: 500 mg
- Powder for suspension: 125 mg/5 mL
Registered products in the Philippines
5 products registered with the Food and Drug Administration (FDA) Philippines list Cefadroxil as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products5
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
Cefadrox-500Cefadroxil | 500 mg CapsuleAlu-Alu Blister Pack x 10's (Box of 60's) | Rx | XL Laboratories Pvt. Ltd.India | Checktrade Pharma, Inc.Importer: Ambica International Corporation | DRP-3317-01 | Jun 30, 2027 | |
Droxanil-500Cefadroxil | 500 mg CapsuleAlu/Alu Blister Pack x 10's (Box of 60's) | Rx | XL Laboratories Pvt. Ltd.India | Pathfinder Pharmacy & DistributorImporter: Ambica International Corporation | DRP-3317-03 | Jun 30, 2027 | |
DrozidCefadroxil (as monohydrate) | 125 mg/5 mL Powder for SuspensionAmber Glass Bottle x 60 mL (Box of 1's) | Rx | PT Dexa MedicaIndonesia | Glorious Dexa Mandaya, Inc. | DRP-8080 | Aug 1, 2027 | |
DROZIDCEFADROXIL | 500 MG CAPSULE | Rx | — | Importer: GLORIOUS DEXA MANDAYA, INC. | DRP-8421 | Feb 12, 2027 | |
Wincocef-500Cefadroxil | 500 mg CapsuleAlu/Alu Blister Pack x 10's (Box of 60's) | Rx | XL Laboratories Pvt. Ltd.India | Checktrade TradingImporter: Ambica International Corporation | DRP-3317 | Jun 30, 2027 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Warnings/Precautions
Warnings and precautions (US label) US FDA label
WARNINGS BEFORE THERAPY WITH CEFADROXIL IS INSTITUTED, CAREFUL INQUIRY SHOULD BE MADE TO DETERMINE WHETHER THE PATIENT HAS HAD PREVIOUS HYPERSENSITIVITY REACTIONS TO CEFADROXIL, CEPHALOSPORINS, PENICILLINS, OR OTHER DRUGS. IF THIS PRODUCT IS TO BE GIVEN TO PENICILLIN-SENSITIVE PATIENTS, CAUTION SHOULD BE EXERCISED BECAUSE CROSS-SENSITIVITY AMONG BETA-LACTAM ANTIBIOTICS HAS BEEN CLEARLY DOCUMENTED AND MAY OCCUR IN UP TO 10% OF PATIENTS WITH A HISTORY OF PENICILLIN ALLERGY.
IF AN ALLERGIC REACTION TO CEFADROXIL OCCURS, DISCONTINUE THE DRUG. SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED.
Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including cefadroxil, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile. C. difficile produces toxins A and B which contribute to the development of CDAD.
Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.
If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.
Drug interactions
| Drug or class | Severity | Effect | What to do |
|---|---|---|---|
| Coombs' (antiglobulin) testing | Minor | Positive direct Coombs' test may be due to the drug, including in newborns of mothers treated before delivery (label). | Consider the drug when interpreting the test. |
Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.
renalcarematters.com, reviewedAdverse reactions
Common
- Diarrhea; dyspepsia, nausea and vomiting (rare)
- Rash, urticaria
Serious
- Anaphylaxis, angioedema
- Clostridioides difficile-associated diarrhea
Adverse reactions (US label) US FDA label
ADVERSE REACTIONS Gastrointestinal Onset of pseudomembranous colitis symptoms may occur during or after antibiotic treatment (see WARNINGS). Dyspepsia, nausea and vomiting have been reported rarely. Diarrhea has also occurred. Hypersensitivity Allergies (in the form of rash, urticaria, angioedema, and pruritus) have been observed.
These reactions usually subsided upon discontinuation of the drug. Anaphylaxis has also been reported. Other Other reactions have included hepatic dysfunction including cholestasis and elevations in serum transaminase, genital pruritus, genital moniliasis, vaginitis, moderate transient neutropenia, fever. Agranulocytosis, thrombocytopenia, idiosyncratic hepatic failure, erythema multiforme, Stevens-Johnson syndrome, serum sickness, and arthralgia have been rarely reported.
In addition to the adverse reactions listed above which have been observed in patients treated with cefadroxil, the following adverse reactions and altered laboratory tests have been reported for cephalosporin-class antibiotics: Toxic epidermal necrolysis, abdominal pain, superinfection, renal dysfunction, toxic nephropathy, aplastic anemia, hemolytic anemia, hemorrhage, prolonged prothrombin time, positive Coombs’ test, increased BUN, increased creatinine, elevated alkaline phosphatase, elevated aspartate aminotransferase (AST), elevated alanine aminotransferase (ALT), elevated bilirubin, elevated LDH, eosinophilia, pancytopenia, neutropenia. Several cephalosporins have been implicated in triggering seizures, particularly in patients with renal impairment, when the dosage was not reduced (see DOSAGE AND ADMINISTRATION and OVERDOSAGE).
If seizures associated with drug therapy occur, the drug should be discontinued. Anticonvulsant therapy can be given if clinically indicated.
Monitoring parameters
- CrCl for dose; kidney function tests when indicated (label); diarrhea (CDAD). Kidney
- CrCl for dose
Pregnancy considerations
Pregnancy (US label) US FDA label
Pregnancy: Pregnancy Category B Reproduction studies have been performed in mice and rats at doses up to 11 times the human dose and have revealed no evidence of impaired fertility or harm to the fetus due to cefadroxil monohydrate. There are, however, no adequate and well controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.
Breastfeeding considerations
Lactation (US label) US FDA label
Nursing Mothers Caution should be exercised when cefadroxil monohydrate is administered to a nursing mother.
Pharmacokinetics
Key PK parameters
| Renal excretion kidney | Over 90% unchanged in urine within 24 hours |
|---|---|
| Dialyzability kidney | Yes (about 63% per 6- to 8-hour hemodialysis) |
Over 90% of the drug is excreted unchanged in the urine within 24 hours.
Increases in dosage generally produce a proportionate increase in cefadroxil urinary concentration.
The urine antibiotic concentration, following a 1 g dose, was maintained well above the MIC of susceptible urinary pathogens for 20 to 22 hours.
Pharmacokinetics (US label) US FDA label
CLINICAL PHARMACOLOGY Cefadroxil is rapidly absorbed after oral administration. Following single doses of 500 mg and 1000 mg, average peak serum concentrations were approximately 16 and 28 mcg/mL, respectively. Measurable levels were present 12 hours after administration. Over 90% of the drug is excreted unchanged in the urine within 24 hours.
Peak urine concentrations are approximately 1800 mcg/mL during the period following a single 500 mg oral dose. Increases in dosage generally produce a proportionate increase in cefadroxil urinary concentration. The urine antibiotic concentration, following a 1 g dose, was maintained well above the MIC of susceptible urinary pathogens for 20 to 22 hours.
Microbiology In vitro tests demonstrate that the cephalosporins are bactericidal because of their inhibition of cell-wall synthesis. Cefadroxil has been shown to be active against the following organisms both in vitro and in clinical infections (see INDICATIONS AND USAGE): Beta-hemolytic streptococci Staphylococci, including penicillinase-producing strains Streptococcus (Diplococcus) pneumoniae Escherichia coli Proteus mirabilis Klebsiella species Moraxella (Branhamella) catarrhalis Note: Most strains of Enterococcus faecalis (formerly Streptococcus faecalis) and Enterococcus faecium (formerly Streptococcus faecium) are resistant to cefadroxil.
It is not active against most strains of Enterobacter species, Morganella morganii (formerly Proteus morganii), and P. vulgaris. It has no activity against Pseudomonas species and Acinetobacter calcoaceticus (formerly Mima and Herellea species). Susceptibility Testing For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA for this drug, please see: https://www.fda.gov/STIC.
Formulary and pricing (Philippines)
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. Cefadroxil · Redpharm Drug [US FDA-approved label, version 1, April 18, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4fb524c1-f985-2a8f-e063-6394a90aab7f
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- Redpharm Drug. (2026). Cefadroxil capsules, USP [Prescribing information; US FDA-approved label, ANDA065352, set ID 4fb524c1-f985-2a8f-e063-6394a90aab7f, version effective April 18, 2026]. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4fb524c1-f985-2a8f-e063-6394a90aab7f
- Aurobindo Pharma Limited. (2024). Cefadroxil capsules, USP [Prescribing information; US FDA-approved label, ANDA065352, set ID 7bb90096-14d3-400e-94d3-048bff6b1292, version 13, effective January 30, 2024; Precautions]. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7bb90096-14d3-400e-94d3-048bff6b1292
renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.
Last updated: .